The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis

Akshjot Puri, Jade Homsi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Immunotherapy has been in use for the treatment of melanoma since a very long time, but only recently have the cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody ipilimumab and programmed cell death-1 inhibitors such as nivolimumab and pembrolizumab been shown to induce marked improvements in survival in patients with metastatic melanoma. An important concern arises in terms of the safety of the use of these agents in patients with autoimmune diseases, solid organ transplant recipients on immunosuppression, patients with a history of previous hepatitis B or C, and patients with HIV infections as these patients were excluded from pivotal immunotherapy studies. Here, we report on the safety and efficacy of pembrolizumab in a melanoma patient with multiple medical problems including poorly controlled rheumatoid arthritis and we review the available literature on the use of immunotherapy and autoimmune diseases. The weight of evidence suggests that these patients should be offered the opportunity to benefit from immune check point inhibitors, with drugs targeting programmed cell death-1 being preferred. More research is required to study the long-term effects of immunotherapy on patients with autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)519-523
Number of pages5
JournalMelanoma Research
Volume27
Issue number5
DOIs
StatePublished - Jan 1 2017

Fingerprint

Melanoma
Rheumatoid Arthritis
Safety
Immunotherapy
Autoimmune Diseases
Cell Death
CTLA-4 Antigen
Proxy
Drug Delivery Systems
Hepatitis C
pembrolizumab
Hepatitis B
Immunosuppression
HIV Infections
Transplants
Weights and Measures
Survival
Antibodies
Research

Keywords

  • Exacerbation
  • Immune-related adverse events
  • Metastatic melanoma
  • Pembrolizumab
  • Rheumatoid arthritis
  • Safety

ASJC Scopus subject areas

  • Oncology
  • Dermatology
  • Cancer Research

Cite this

The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis. / Puri, Akshjot; Homsi, Jade.

In: Melanoma Research, Vol. 27, No. 5, 01.01.2017, p. 519-523.

Research output: Contribution to journalArticle

@article{60324df499b04c71b1722233cb2f1891,
title = "The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis",
abstract = "Immunotherapy has been in use for the treatment of melanoma since a very long time, but only recently have the cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody ipilimumab and programmed cell death-1 inhibitors such as nivolimumab and pembrolizumab been shown to induce marked improvements in survival in patients with metastatic melanoma. An important concern arises in terms of the safety of the use of these agents in patients with autoimmune diseases, solid organ transplant recipients on immunosuppression, patients with a history of previous hepatitis B or C, and patients with HIV infections as these patients were excluded from pivotal immunotherapy studies. Here, we report on the safety and efficacy of pembrolizumab in a melanoma patient with multiple medical problems including poorly controlled rheumatoid arthritis and we review the available literature on the use of immunotherapy and autoimmune diseases. The weight of evidence suggests that these patients should be offered the opportunity to benefit from immune check point inhibitors, with drugs targeting programmed cell death-1 being preferred. More research is required to study the long-term effects of immunotherapy on patients with autoimmune diseases.",
keywords = "Exacerbation, Immune-related adverse events, Metastatic melanoma, Pembrolizumab, Rheumatoid arthritis, Safety",
author = "Akshjot Puri and Jade Homsi",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/CMR.0000000000000387",
language = "English (US)",
volume = "27",
pages = "519--523",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis

AU - Puri, Akshjot

AU - Homsi, Jade

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Immunotherapy has been in use for the treatment of melanoma since a very long time, but only recently have the cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody ipilimumab and programmed cell death-1 inhibitors such as nivolimumab and pembrolizumab been shown to induce marked improvements in survival in patients with metastatic melanoma. An important concern arises in terms of the safety of the use of these agents in patients with autoimmune diseases, solid organ transplant recipients on immunosuppression, patients with a history of previous hepatitis B or C, and patients with HIV infections as these patients were excluded from pivotal immunotherapy studies. Here, we report on the safety and efficacy of pembrolizumab in a melanoma patient with multiple medical problems including poorly controlled rheumatoid arthritis and we review the available literature on the use of immunotherapy and autoimmune diseases. The weight of evidence suggests that these patients should be offered the opportunity to benefit from immune check point inhibitors, with drugs targeting programmed cell death-1 being preferred. More research is required to study the long-term effects of immunotherapy on patients with autoimmune diseases.

AB - Immunotherapy has been in use for the treatment of melanoma since a very long time, but only recently have the cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody ipilimumab and programmed cell death-1 inhibitors such as nivolimumab and pembrolizumab been shown to induce marked improvements in survival in patients with metastatic melanoma. An important concern arises in terms of the safety of the use of these agents in patients with autoimmune diseases, solid organ transplant recipients on immunosuppression, patients with a history of previous hepatitis B or C, and patients with HIV infections as these patients were excluded from pivotal immunotherapy studies. Here, we report on the safety and efficacy of pembrolizumab in a melanoma patient with multiple medical problems including poorly controlled rheumatoid arthritis and we review the available literature on the use of immunotherapy and autoimmune diseases. The weight of evidence suggests that these patients should be offered the opportunity to benefit from immune check point inhibitors, with drugs targeting programmed cell death-1 being preferred. More research is required to study the long-term effects of immunotherapy on patients with autoimmune diseases.

KW - Exacerbation

KW - Immune-related adverse events

KW - Metastatic melanoma

KW - Pembrolizumab

KW - Rheumatoid arthritis

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85044433170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044433170&partnerID=8YFLogxK

U2 - 10.1097/CMR.0000000000000387

DO - 10.1097/CMR.0000000000000387

M3 - Article

C2 - 28817445

AN - SCOPUS:85044433170

VL - 27

SP - 519

EP - 523

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 5

ER -